InvestorsHub Logo
Followers 10
Posts 388
Boards Moderated 0
Alias Born 12/27/2017

Re: monte379 post# 68852

Wednesday, 12/05/2018 6:59:46 PM

Wednesday, December 05, 2018 6:59:46 PM

Post# of 111071
That's true monte. I've been loading my boat a little more each week especially as it hovered just above one cent. I'd wished I had bought a cargo-ship load of shares back in February and March instead of the tiny rented-out used fishing boat, but it's all good. Right now it appears the pps is really really attractive to the newest investors lucky and willing enough to get in now before the peer review results come back reporting on their trials. I'm really confident there'll be good news and when it comes out we'd all better pull up the anchors from our ships before we hit full thrust. ... Now if I had a super tanker all filled up by now I could just wait it out at sea. Of course if CELZ gets bought out just like Medistem did back in 2014 as CELZ now has Thomas E Ichim former President, Director & Chief Scientific Officer of Medistem, Inc. aboard ... well I might be looking to purchase a nice new pleasure craft for myself.

Dang, who is Thomas Ichim anyway?

"Thomas Ichim, Ph.D, Chief Scientific Advisor

Thomas Ichim, Ph.D, Chief Scientific Advisor, has more than 20 years of broad biotechnology experience including filing and prosecuting patents (over 100 patents filed and issued), publishing in peer reviewed journals (110 publications) obtaining regulatory approvals, conducting clinical trials, and successfully providing return to investors by taking companies public or selling of companies. Dr. Ichim was cofounder of bioRASI, a fully integrated CRO which made the INC 500 list for fastest growing companies in the USA. He subsequently joined Medistem Inc, a stem cell company which was purchased by the NYSE traded company Intrexon. Dr. Ichim was co-founder of Batu Biologics, a cancer vaccine, Regen BioPharma, and Creative Medical Technology Holdings, both of which he successfully took public. Dr. Ichim is peer-reviewed for multiple scientific journals and sits on the Editorial Board of the Journal of Translational Medicine. Dr. Ichim is author/coauthor of multiple book chapters and 3 textbooks"

http://www.spinalcyte.com/company.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CELZ News